Edition:
United States

Immunicum AB (IMMUN.ST)

IMMUN.ST on Stockholm Stock Exchange

18.90SEK
9:49am EDT
Change (% chg)

-0.70kr (-3.57%)
Prev Close
19.60kr
Open
19.30kr
Day's High
19.60kr
Day's Low
18.30kr
Volume
20,775
Avg. Vol
38,933
52-wk High
32.00kr
52-wk Low
17.60kr

Latest Key Developments (Source: Significant Developments)

Immunicum AB qtrly loss per share before and after dilution amounted to Sek 0.80
Friday, 19 May 2017 12:35am EDT 

May 19 (Reuters) - Immunicum AB :Qtrly loss per share before and after dilution amounted to sek 0.80.  Full Article

Immunicum says uplisting to Nasdaq Stockholm postponed
Friday, 24 Mar 2017 11:35am EDT 

Immunicum AB : Says its uplisting to Nasdaq Stockholm postponed . Says Stockholm's listing committee has postponed decision on Immunicum's application for admission to trading .Says committee noted company needs to demonstrate it will continue to apply them for a longer period before committee can make a final decision on its application.  Full Article

Immunicum Q2 2016/17 operating loss widens to SEK 24.7 mln
Friday, 17 Feb 2017 01:30am EST 

Immunicum AB : Q2 2016/17 operating loss 24.7 million Swedish crowns ($2.8 million) versus loss 11.2 million crowns year ago .Q2 2016/17 net loss 24.8 million crowns versus loss 11.5 million crowns year ago.  Full Article

Immunicum Q1 operating loss widens to SEK 12.0 million
Friday, 18 Nov 2016 02:30am EST 

Immunicum AB :Q1 operating loss 12.0 million Swedish crowns ($1.3 million)versus loss 7.8 million crowns year ago.  Full Article

Immunicum announces Carlos de Sousa as new CEO
Tuesday, 27 Sep 2016 02:30am EDT 

Immunicum AB : Announces Carlos de Sousa as new CEO . De Sousa will replace Jamal El-Mosleh, Immunicum's CEO since Sept. 2007, who will now work with de Sousa to assure a smooth and seamless transition .Appointment of Carlos de Sousa as Immunicum's Chief Executive Officer is effective on Oct. 1, 2016.  Full Article

Immunicum Q4 operating loss widens to SEK 15.1 mln
Wednesday, 31 Aug 2016 02:30am EDT 

Immunicum AB : Q4 operating loss 15.1 million Swedish crowns ($1.77 million) versus loss 8.2 million crowns year ago .Q4 net loss 15.0 million crowns versus loss 7.8 million crowns year ago.  Full Article

Immunicum will receive patent application in China on CD70
Tuesday, 26 Jul 2016 03:01am EDT 

Immunicum AbB :Announced that a patent application in China regarding the company's CD70-technology will be granted.  Full Article

Immunicum submits IND application to FDA
Friday, 22 Jul 2016 09:28am EDT 

Immunicum AB : Submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) in the U.S . The application is requesting approval to treat kidney cancer patients in the U.S. with Immunicum's lead cancer immune primer, INTUVAX, in its ongoing MERECA (MEtastatic REnal cell CArcinoma) phase II-trial . As previously reported, results from Immunicum's completed phase I/II-trial for treatment of kidney cancer have been promising .Approval from the FDA is expected within 30 days.  Full Article

Immunicum Q3 2015/16 operating loss narrows to SEK 9.5 million
Friday, 20 May 2016 02:49am EDT 

Immunicum AB :Q3 2015/16 operating loss 9.5 million Swedish crowns ($1.14 million) versus loss 10.7 million crowns.  Full Article

Immunicum Q3 2015/16 operating loss narrows to SEK 9.5 million
Friday, 20 May 2016 02:49am EDT 

Immunicum AB :Q3 2015/16 operating loss 9.5 million Swedish crowns ($1.14 million) versus loss 10.7 million crowns.  Full Article

More From Around the Web